Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709904 · ClinicalTrials.gov registry record · Phase 3
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 469
- Enrollment target
NCT00709904 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 469 participants.
The verdict
NCT00709904, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 469 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis with open-label AVE5026 in patients having undergone hip fracture surgery. The secondary objective is to evaluate the safety of extended AVE5026 administration.
Interventions
- DRUG Semuloparin sodium
- DRUG Open-label Semuloparin sodium
- DRUG Placebo (for Semuloparin sodium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709904
The ClinicalTrials.gov registry entry for NCT00709904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semuloparin sodium is the first listed.
NCT00709904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00709904 about?
NCT00709904 is a clinical study titled "Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery". The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis with open-label AVE5026 in patients having undergone hip fracture surgery...
What is the current status of trial NCT00709904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 469 participants. The study started on 2008-06. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00709904?
The interventions under investigation include: Semuloparin sodium (DRUG), Open-label Semuloparin sodium (DRUG), Placebo (for Semuloparin sodium) (DRUG).
Who is sponsoring clinical trial NCT00709904?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.